Dr. Sandra Algaze
Medical Oncology (Medical Oncology Physician)
1441 Eastlake Ave
Los Angeles, CA 90089
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 130
Licensed in California since 2018, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license A156237 (first issued 2018; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Keck Hospital of Usc Los Angeles, CA
- Los Angeles General Medical Center Los Angeles, CA
Medical groups
- Usc Care Medical Group Inc (1,380 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 130
- Services billed
- 765
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 343 | 53 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 72 | 25 |
| New patient office or other outpatient visit, 60-74 minutes | 29 | 28 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 28 | 24 |
| Established patient office or other outpatient visit, 30-39 minutes | 23 | 20 |
| Hospital discharge day management, more than 30 minutes | 20 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Furosemide Other prescribers in Los Angeles, CA | 21 |
| Ondansetron Odt (ondansetron) Other prescribers in Los Angeles, CA | 15 |
| Loperamide (loperamide hcl) Other prescribers in Los Angeles, CA | 14 |
| Prednisone Other prescribers in Los Angeles, CA | 14 |
| Zenpep (lipase/protease/amylase) Other prescribers in Los Angeles, CA | 13 |
| Triamcinolone Acetonide Other prescribers in Los Angeles, CA | 12 |
| Amlodipine Besylate Other prescribers in Los Angeles, CA | 11 |
| Eliquis (apixaban) Other prescribers in Los Angeles, CA | 11 |
| Omeprazole Other prescribers in Los Angeles, CA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 18 payments worth $7,160 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $3,780 |
|---|---|
| Incyte Corporation | $3,180 |
| Genzyme Corporation | $52.08 |
| Caris Mpi, Inc. | $35.34 |
| Sobi, Inc | $31.49 |
| Janssen Biotech, Inc. | $30.81 |
| Merck Sharp & Dohme LLC | $25.70 |
| AstraZeneca Pharmaceuticals LP | $24.55 |
| Consulting Fee | $6,255 |
|---|---|
| Food and Beverage | $494 |
| Travel and Lodging | $385 |
| Education | $25.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Feb 28, 2025 | Consulting Fee | $3,780 |
| Incyte Corporation Feb 14, 2025 | Consulting Fee ZYNYZ · Oncology | $2,475 |
| Incyte Corporation Jan 26, 2025 | Travel and Lodging ZYNYZ · Oncology · travel to San Francisco, CA | $138 |
| Incyte Corporation Jan 22, 2025 | Travel and Lodging ZYNYZ · Oncology · travel to San Francisco, CA | $105 |
| Incyte Corporation Jan 22, 2025 | Travel and Lodging ZYNYZ · Oncology · travel to San Francisco, CA | $64.69 |
| Incyte Corporation Jan 22, 2025 | Travel and Lodging ZYNYZ · Oncology · travel to San Francisco, CA | $52.38 |
| Merck Sharp & Dohme LLC Oct 14, 2025 | Education in-kind | $25.70 |
| Incyte Corporation Jan 22, 2025 | Travel and Lodging ZYNYZ · Oncology · travel to San Francisco, CA | $24.41 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $91,410 in research payments for these studies, mostly to the institutions running them.
- Fruquintinib
Takeda Pharmaceuticals U.S.A., Inc. - A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
AbbVie Inc. · Recruiting · NCT07023289
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.